Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer

Gefitinib showed response in phase II clinical trials and with better clinical response in lung cancer with activating mutations in the tyrosine kinase domain of the EGFR. Questions of toxicity and potential dosing regimens impede the use in a prevention setting. This study will provide scientific e...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Zhang, Qi, Li, Ruichao, Chen, Xu, Lee, Sang Beom, Pan, Jing, Xiong, Donghai, Hu, Jiaqi, Miller, Mark Steven, Szabo, Eva, Lubet, Ronald A., Wang, Yian, You, Ming
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2017
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5641144/
https://ncbi.nlm.nih.gov/pubmed/29069801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19785
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia